Find a Program
Find a Lab
Bonnie J. and Anthony Addario Endowed Chair in Thoracic Oncology
The newly created Chair in Thoracic Oncology is in honor of thoracic oncologist Thierry Jahan, M.D.
Lung Cancer Foundation's Annual Gala on Saturday, Nov. 21, 2009
A benefit for Lung Cancer Research and to celebrate the Addario Lung Cancer Medical Institute.
Make a Gift
A gift to the Thoracic Oncology Progam helps us discover new treatments and cures for lung cancer, esophageal cancer and mesothelioma.
Michael Mann, M.D.
Associate Professor of Surgery
Chief of General Thoracic Surgery, San Francisco VA MedicalCenter
Contact Information
Education
- 1981-85, Princeton University, A.B. , Chemistry
- 1985-91, Stanford University, MD , Medicine
Residencies
-
Stanford University, Intern, Surgery
-
Stanford University, Resident, General Surgery
-
Brigham and Women's Hospital/Harvard Medical School, Resident, General Surgery
-
University of California, San Francisco School of Medicine, Resident, Cardiothoracic Surgery
Fellowships
- Stanford University, Postdoctoral Fellow
- NIH Ruth L. Kirschstein National Research Service Award (NRSA) Research Training Fellowship, Cardiovascular Disease
Board Certification
- American Board of Surgery
- American Board of Thoracic Surgery
Program Affiliations
- Division of Adult Cardiothoracic Surgery, Section of General Thoracic Surgery
- Thoracic Oncology Program
- UCSF Helen Diller Family Comprehensive Cancer Center
- Heart and Lung Transplantation Program
- UCSF Cardiovascular Research Institute
Clinical Expertise
- Beating heart bypass
- Coronary revascularization
- Lung Cancer
- Lung volume reduction surgery
- Mediastinal Masses
- Mesothelioma
- Minimally Invasive Chest Surgery
- Valve and aortic surgery
- Ventricular reconstructive techniques
Research Interests
-
Cardiovascular cell cycle biology
-
Cardiovascular tissue engineering
-
Molecular and cell biology
-
Molecular genetics of heart disease
-
Myocardial gene therapy
-
Stem and progenitor cell transplantation for cardiovascular regeneration
-
Stem cell biology in cancer
-
Therapeutic neovascularization for ischemic disease
-
Translational Medicine
Biography
Michael Mann, M.D. joined the Thoracic Oncology Program in 2003 as a cardiothoracic surgeon. He received his M.D. from Stanford University and was awarded a Ruth L. Kirschstein National Research Service Award (NRSA) Research Training Fellowship through the NIH. Dr. Mann completed his General Surgery residency at Brigham and Women's Hospital/Harvard Medical School and his Cardiothoracic Surgery fellowship at UCSF.
Dr. Mann is Chief of Thoracic Surgery at the San Francisco VA Medical Center and an attending surgeon at the UCSF Medical Center. His areas of expertise include lung cancer, mesothelioma, esophageal cancer, sarcoma and minimally invasive (video-assisted) thoracoscopic surgery. He also has expertise in performing cardiac procedures including coronary bypass, valve replacement, and aortic reconstruction.
Dr. Mann is widely admired for his teaching skills and is Assistant Director of the Thoracic Surgery Training Program. He holds memberships in numerous professional organizations including the Society of Thoracic Surgeons, American College of Surgeons, American Heart Association, American College of Cardiology and the Massachusetts Medical Society. He has received numerous awards including the Cardiovascular Medicine Award for Excellence in Research, Dean's Award for Excellence in Research, and William Randolph Hearst Endowment for Young Investigators. Dr. Mann also serves as a scientific reviewer for numerous professional journals.
While on the faculty at Harvard Medical School, Dr. Mann founded the Cardiovascular Gene Therapy Group. He also invented several novel drug and delivery technologies and helped pioneer the application of gene regulation and vascular biology principles to the problem of coronary bypass graft failure. This led to one of the first large scale programs to evaluate the integration of molecular therapy into cardiac surgery.
Dr. Mann's research in genetic and molecular therapies has been widely recognized. He is currently an Associate Investigator in the UCSF Cardiovascular Research Institute. Dr. Mann also serves as a scientific advisor to the American Heart Association, the NIH Recombinant-DNA Advisory Committee, and to numerous device and pharmaceutical companies.
Selected Publications
-
Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, Cooke JP, Kaneda Y, Dzau VJ. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci U S A. 92: 4502-6, May/9/1995.
-
Mann MJ, Gibbons GH, Hutchinson H, Poston RS, Hoyt EG, Robbins RC, Dzau VJ. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci U S A. 96: 6411-6, May/25/1999.
-
Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, Orav EJ, Ehsan A, Dell'Acqua G, Dzau VJ. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet. 354: 1493-8, Oct/30/1999.
-
Braun-Dullaeus RC, Mann MJ, Sedding DG, Sherwood SW, von der Leyen HE, Dzau VJ. Cell cycle-dependent regulation of smooth muscle cell activation. Arterioscler Thromb Vasc Biol. 24: 845-50, May/2004.
-
Mann MJ, Tendulkar A, Birger N, Howard C. Ratcliffe MB. NIH funding for surgical research. Ann Surg. (In Press) , 2007.
In the News
Advancing the Treatment of Adult Soft Tissue Sarcomas
Orthopedic Surgery News at UCSF Medical Center - Dec 25, 2008"Soft tissue sarcomas are extraordinarily heterogeneous, so experience is particularly important when deciding among treatment options," says medical oncologist Thierry M. Jahan, M.D. (pictured right). At UCSF, referring physicians typically send patients with painful, growing soft tissue masses to orthopaedic surgeon Richard J. O'Donnell, M.D., and general surgeon Eric K. Nakakura, M.D., Ph.D, (pictured left). If their initial examination convinces them that there is a sarcoma concern, they move on to a staging workup that includes various imaging modalities and, eventually, either a needle or incisional biopsy...."
The Problem of Funding in Surgical Research
Scientists and Engineers for America (SEA) - May 20, 2008"Surgeons may be capable of accelerating the translation of basic research into new clinical therapies. Nevertheless, most surgeon-scientists believe they are at a disadvantage in competing for peer-reviewed funding, despite a recent emphasis on "translational science" by organizations such as the NIH."
